Semiconductors on Korea Invest Insights

Korea Quality Re-Rating Watch: SK Hynix, SK Square and Jeoryong

Tue, 28 Apr 2026 16:30:00 +0900

Section 1: Macro Dashboard

Indicator	Level	5D Change	Signal
KOSPI	6,641.0	+3.5%	Bull
KOSDAQ	1,215.6	+2.9%	Bull
VIX	18.5	−2.4%	Stable
US 10Y	4.34%	+0.04pp	Neutral
USD/KRW	1,475	−0.7%	Neutral
Brent	$104.6	−0.5%	Stable

Regime Verdict — KR: Bull / US: Bull. Breadth remains broad: 68.1% of KR universe above 50MA, 60.1% above 200MA. KR–US co-movement is positive and the operating stance is aggressive expansion. Won strengthening marginally reduces import pressure. VIX at 18.5 is non-threatening.

Section 2: Market Wrap

Korea’s session on April 27 was unambiguously risk-on. KOSPI extended to +2.51% intraday and KOSDAQ added +1.83%, with both indices benefiting from synchronized foreign and institutional buying — a quality signal, not just retail chasing.

Sector leadership was narrow but forceful. Semiconductors and HBM names were the day’s primary engine, driven by Intel’s strong US results overnight and a surge in the Philadelphia Semiconductor Index. SK Hynix (000660.KS) added over 6% and pulled the broader chip ecosystem higher. Power equipment was the second major axis — AI data center infrastructure demand is translating into real order flow and margin expansion for Korean transformer and switchgear makers. Marine engine and machinery stocks, particularly those with LNG carrier and data center engine exposure, participated strongly. Robotics/physical AI was a notable satellite theme with several smaller names posting double-digit moves.

The weak axis consisted of defensives — telecoms, pharma, and select secondary battery names lagged, consistent with a day where risk appetite tilted toward cyclicals. This is characteristic rotation, not broad deterioration.

Flow picture was constructive overall though not uniform. Foreign buying was concentrated in high-conviction semiconductor names, while institutional money was more active in power equipment and machinery. The divergence between strong price action in large-cap semis and residual foreign selling in some names underscores the importance of verifying flow before extending positions.

Market breadth — 211 names passing the operating screener — confirms the rally was not a single-stock event. The KR screener has been in BULL territory for 18 consecutive days (Discovery 100/100, Day 18), which reduces the probability that this is a low-quality short-squeeze scenario.

Key tactical note from the close briefing: Hanwha Engine (082740.KS) surged +16.5% on a 1Q26 earnings beat (+15% vs. consensus) and a broker target price raise to ₩100,000. LNGC engine margins are expanding from high-single to mid-teens percent, and US data center engine inquiry flow is an emerging catalyst. The 5-day gain of +63% places timing in overheated territory — the quality thesis strengthens but entry discipline matters.

Section 3: Today’s Quality Re-Rating Candidates

The April 28 Meta Screener processed 139 tickers and surfaces 20 ranked candidates. Two names score above 90 and both hit 4+ screeners. The editorial lens: good businesses where institutional and foreign capital is actively entering and the market is beginning to re-price the earnings story.

Top Candidates Table

Rank	Ticker	Name	Meta Score	Overlap	Screeners Hit	ROE	OP YoY	RS%
1	000660.KS	SK Hynix	92.5	4	QC, SMQ, CR, SME, CU	44.1%	+101.2%	98.5
2	402340.KS	SK Square	90.5	4	QC, SMQ, CR, SME	37.8%	+124.4%	99.1
3	420770.KQ	Gigavis	65.4	3	QC, SMQ, SME	7.4%	—	97.1
4	006910.KQ	Bosung Powertech	64.9	3	QC, SMQ, PEAD	20.3%	+458.3%	95.4
5	017510.KQ	Semyung Electric	63.8	3	QC, SMQ, SME	15.1%	+393.3%	77.6
6	425420.KQ	TFI	63.5	4	QC, SMQ, SME, PEAD	19.3%	+334.1%	93.4
7	147830.KQ	Jeoryong Industrial	62.3	3	QC, SMQ, SME	13.9%	+158.5%	79.9
8	088130.KQ	Dong-A Eltek	48.4*	3	SMQ, CR, SME	33.6%	+670.1%	97.8
9	062040.KQ	Sanil Electric	58.6	2	QC, SMQ	29.2%	—	94.0
10	053610.KQ	Protek	57.4	2	QC, SMQ, CU	14.6%	—	95.3

QC = Quality Compounder, SMQ = Smart Money Quality, CR = Cycle Rerating, SME = Smart Money Earnings, CU = Consensus Up Revision, PEAD = Post-Earnings Drift

Dong-A Eltek (088130.KQ) meta rank is 14 but overlap count is 3 including the Cycle Rerating screener — included for cycle signal strength.

Deep Dive: Top 3 Names

1. SK Hynix (000660.KS) — Meta Rank #1, Score 92.5

SK Hynix is Korea’s dominant HBM and DRAM manufacturer, a critical supplier to NVIDIA’s AI accelerator stack and the global HBM3e market. It hits all five screener layers: Quality Compounder (ROE 44.1%, operating margin 48.6%, OP YoY +101.2%), Smart Money Quality (5D net foreign + institutional flow: +₩147.2bn), Cycle Rerating (margin expansion +13.1pp), Smart Money Earnings, and Consensus Up Revision. This is the highest-conviction configuration the framework can generate. One DART risk filing was flagged today (early redemption of exchangeable bonds, 20260428); routine for a company this size but worth noting. What to check next: whether foreign flow, which was mixed at the close briefing date (April 24 data), has turned decisively net buying as of April 28. The price momentum is strong (RS 98.5, near 52-week high) but confirmation of reinvigorated foreign accumulation is the gating condition before treating this as a primary entry rather than a hold.

2. SK Square (402340.KS) — Meta Rank #2, Score 90.5

SK Square is SK Hynix’s holding parent and a pure-play on Korea’s AI/semiconductor rerating cycle, with the added optionality of a portfolio of tech assets (T-map Mobility, 11Street, Incross, etc.) and active shareholder return activity. The screener profile is nearly as strong as SK Hynix: QC rank #1 (the highest quality compounder score in today’s universe at 0.966), Cycle Rerating with margin expansion of +17.5pp and OP YoY +124.4%, Smart Money Quality with 5D F+I inflows of +₩140.1bn, and Smart Money Earnings. Two DART catalyst filings (subsidiary dividend announcements, April 22) are positive; one risk filing (exchangeable bond early redemption, today) mirrors SK Hynix’s. Trading at P/E 12.2x with ROE 37.8%, the valuation discount to NAV is the re-rating argument. What to check next: subsidiary valuation updates, particularly any announcements around T-map or 11Street, and whether the holding company discount is narrowing in broker models.

3. Jeoryong Industrial (147830.KQ) — Meta Rank #8, Overlap Rank #5

Jeoryong Industrial manufactures structural metal products and power infrastructure components — directly exposed to the AI data center and grid upgrade capex cycle driving today’s broader power equipment theme. It clears three screeners: Quality Compounder (ROE 13.9%, low debt at 11.4%, OP YoY +158.5%), Smart Money Quality (5D F+I +₩4.5bn — modest in absolute terms but meaningful for a small-cap), and Smart Money Earnings. No DART filings to flag. The RS of 79.9 is the weakest among the top names — this is a mid-tier momentum name, not a breakout leader. What to check next: order backlog composition (domestic grid vs. export), margin trajectory sustainability, and whether the 5D flow can be confirmed as institutional accumulation rather than one-off retail activity. The power equipment theme is validated by today’s broad sector strength; Jeoryong is a second-derivative way to play it with quality fundamentals but without the large-cap premium.

Disclaimer: For research and information purposes only. Not investment advice. Names cited are for analytical illustration; readers should perform their own due diligence and consult licensed advisors before any investment decision.

Korea Daily Wrap Apr 27: Semis, Power and PEAD Leaders Rally

Mon, 27 Apr 2026 16:30:00 +0900

Macro Dashboard

Indicator	Level	5-Day Change	Signal
KOSPI	6,615.0	+3.5%	Bullish
KOSDAQ	1,226.2	+4.0%	Bullish
VIX	18.96	−2.8%	Stable
US 10Y	4.31%	+0.06pp	Neutral
USD/KRW	1,470	+0.1%	Stable
Brent	$100.37	−1.5%	Stable

Regime Verdict — KR: Bull | US: Neutral. Breadth above 50-MA sits at 68.0% (KOSPI names), above 200-MA at 60.4%, with 211 names passing the full operating screener. The divergence between a KR Bull and US Neutral regime argues for selective Korea expansion rather than broad index chasing.

Market Wrap

Monday’s Korea session had a single character: broad, conviction-driven risk-on. KOSPI extended intraday gains to +2.51% by 14:20, with KOSDAQ touching +1.83%, both well above early-morning Neutral expectations. The catalyst was a coordinated dual-engine bid — foreign and institutional investors buying together — which is the cleanest breadth signal the market can produce.

Semiconductors and HBM were the session’s undisputed leadership. Intel’s overnight beat in the US, combined with Philadelphia Semiconductor Index strength, imported momentum directly into Korean chipmakers. SK Hynix (000660.KS) surged over +6%, dragging the broader semiconductor complex higher. The move reinforced the thesis that AI infrastructure demand is still accelerating and that Korea’s chip supply chain sits at the center of it.

Power equipment was the second pillar. The AI power infrastructure theme — data center buildout driving demand for high-capacity transformers and switchgear — continues to find incremental buyers. LS ELECTRIC emerged as a standout name in intraday screening, with RS percentile near 98.9, though the session closed at elevated levels after a sharp run.

Machinery and marine engines registered one of the sharpest single-day moves in recent memory. Hanwha Engine (082740.KS) surged +16.5% on 1Q26 operating profit of ₩51.4bn, a +15% beat to consensus, with LNGC slow-speed engine margins expanding from high-single-digit to mid-teen levels. SK Securities raised its target to ₩100,000 from ₩72,000. The five-day move stands at +63%, placing it firmly in momentum-overextension territory near-term.

Robotics added speculative acceleration, with names like Robotis (108490.KQ) printing +19% on physical-AI momentum. That cadence — high RS, high velocity, one-session pop — is typical of momentum clustering in a confirmed bull breadth environment.

The weak side was predictable for a risk-on day: telecom and defensives underperformed on opportunity cost, not company-specific newsflow. Pharma and biotech laggards also stayed quiet. Within secondary batteries, divergence persisted — names with direct AI or power exposure held ground; pure EV-cycle plays did not.

Flow read: The foreign + institutional joint buying that drove today’s session is the most reliable bullish signal in the KRX data. When both actor classes accumulate simultaneously on rising volume, breadth tends to expand further over the following 2–5 sessions. Watch whether this dual-flow pattern repeats Tuesday as the key regime confirmation.

Today’s Screener Spotlight: PEAD (Post-Earnings Announcement Drift)

Monday rotation — PEAD. This screener targets the academically well-documented anomaly where stocks with strong earnings surprises continue to drift in the direction of the surprise for 1–4 weeks post-announcement. The filter requires OP YoY ≥40%, revenue YoY ≥15%, and margin expansion ≥2pp for Tier A names, combined with price confirmation above the 50-day moving average and room to the 52-week high.

Screened as of 2026-04-27 16:20 KST. 92 total candidates: 38 Tier A (Strong Beat), 27 Tier B (Clear Beat), 27 Tier C (Mild Beat).

Tier A — Top 8 by Composite Score

#	Ticker	Name	Close (₩)	OP YoY	Rev YoY	Δ Margin	ROE	RS%	Score
1	489790.KS	Hanwha Vision	88,800	+2,851%	+263%	+7.95pp	5.4%	73	+3.72
2	046940.KQ	Woowon Development	5,650	+2,300%	+24%	+16.92pp	36.8%	78	+2.46
3	005690.KS	Pharmicell	18,930	+630%	+76%	+22.90pp	38.3%	84	+1.82
4	330730.KQ	Stonebridge Ventures	6,690	+297%	+80%	+28.89pp	12.4%	75	+1.82
5	307930.KQ	CompanyK	9,440	+197%	+43%	+23.59pp	9.3%	78	+1.44
6	006910.KQ	Bosung Powertech	12,190	+458%	+91%	+11.92pp	20.3%	97	+1.24
7	100840.KS	SNT Energy	57,500	+401%	+106%	+10.81pp	25.2%	73	+1.21
8	425420.KQ	TFI	65,200	+334%	+52%	+11.09pp	19.3%	95	+0.90

Top 3 in Context

Hanwha Vision (489790.KS) — Korea’s dominant machine-vision and video-surveillance hardware manufacturer, increasingly exposed to AI-inference edge computing and smart factory automation. The OP YoY of +2,851% reflects a low base recovery combined with margin-accretive product mix shift toward AI-enabled cameras. At 4.2% below its 52-week high with a 20-day return of +17.3%, drift runway remains meaningful. RS at 73 is the weakest element of the profile — worth monitoring for institutional flow confirmation.

Woowon Development (046940.KQ) — Mid-cap civil engineering and construction specialist with outsized margin leverage to public infrastructure project cycles. The +16.92pp margin expansion is the largest absolute margin gain in the Tier A cohort, suggesting fixed-cost absorption on a revenue base that grew +24% YoY. The 52-week gap of just 3.6% means it is near highs — PEAD logic argues the drift continues as long as the fundamental catalyst (multi-year project backlog) remains undiscounted.

Pharmicell (005690.KS) — Cell therapy and stem-cell-based regenerative medicine company. The +630% OP YoY on +76% revenue growth and a +22.9pp margin jump signals a transition from R&D burn phase to commercial-scale profitability. Biotech earnings inflections in Korea tend to receive delayed institutional recognition; the 5-day return of −1.4% alongside a strong 20-day return of +20.7% suggests early consolidation rather than reversal — a textbook PEAD setup if the broader market stays constructive.

Korea Daily Wrap 2026-04-23: Large-Cap Quality Surge

Thu, 23 Apr 2026 16:30:00 +0900

Macro Dashboard

Indicator	Level	5-Day Δ	Signal
KOSPI	6,475.8	+4.6%	Bullish
KOSDAQ	1,174.3	+0.4%	Flat
USD/KRW	1,482	+0.3%	Stable
VIX	19.6	+11.8%	Contained
US 10Y	4.29%	−0.02 pp	Flat
Brent	$97.4	+2.0%	Mild bid
DXY	98.8	+0.8%	Dollar firm

Regime Verdict — KR: Bull | US: Bull | Stance: Aggressive Expand

Both markets confirmed Bull on April 22 after a brief Neutral interlude. Breadth remains constructive: 61.4% of the KR universe trades above the 50-day MA, 58.6% above the 200-day. The 4.2-percentage-point gap between KOSPI (+4.6%) and KOSDAQ (+0.4%) over the past five sessions signals a large-cap quality tilt. Watch for a Neutral relapse — an identical setup on April 17 and 21 flipped to Neutral within 24 hours.

Market Wrap

Thursday’s Korea stock market session extended a week-long recovery that has pushed the KOSPI back above 6,475 — a level not seen since early April. The character of today’s trade was a quality-led, large-cap advance: broad enough to sustain a Bull macro regime verdict but narrow enough to leave small-caps virtually unchanged.

Large-caps carried the load. The KOSPI’s five-session gain of 283 points (+4.6%) dwarfs the KOSDAQ’s meager +4.3-point uptick (+0.4%) over the same window, a 4.2-percentage-point divergence that reflects institutional rotation toward liquid, high-quality names rather than a broad risk-on sweep. Market breadth of 61.4% above the 50-day MA confirms participation is real but not euphoric.

Semiconductors and industrial infrastructure dominated themes. The screener data is heavily skewed toward special-purpose machinery and semiconductor-adjacent equipment manufacturers posting triple-digit revenue growth — a sign that investors are pricing in continued capex buildout in AI infrastructure and power/energy grids. Power-equipment and transformer names (Sanil Electric, Semyung Electric, Boseong Powertech) cluster at the top of quality rankings alongside semiconductor blue-chips, suggesting the market is rewarding two adjacent capex cycles simultaneously: AI compute and the grid infrastructure needed to power it.

Foreign and institutional flows tilted supportive. The Discovery sub-signal within the screener has been running at 100/100 for 17 consecutive sessions — an unusually persistent momentum reading that typically reflects sustained foreign or institutional accumulation in the top-tier universe. Combined with VIX at a manageable 19.6 and a stable won (1,482/USD, barely moved), the external backdrop removed the tail-risk premium that had weighed on sentiment in mid-April.

Risks on the radar. Brent’s +2.0% five-session move to $97.4 bears watching: at these levels, imported inflation begins to pressure the Bank of Korea’s already cautious easing calculus. A DXY firming toward 99 alongside oil above $97 is an uncomfortable combination for an import-heavy economy. The previous Bull-to-Neutral regime flip (April 22) was short-lived, but the pattern of brief Bull windows followed by retreats suggests the current leg needs macro confirmation to extend.

Thursday Screener Spotlight: Quality Compounder

Methodology: The Quality Compounder screen filters the 2,722-stock KR universe for the intersection of high fundamental quality (ROE, operating margin, low debt), durable revenue growth, and price trend confirmation (RS85+, Near-52W High). Today 179 names cleared the bar; the top 20 are ranked by a composite strategy score (avg 0.905 for this cohort).

Top 10 Candidates — 2026-04-23

Rank	Ticker	Name	Score	RS %ile	ROE %	Op. Margin %	Rev Growth YoY %	P/E
1	402340.KS	SK Square	0.966	99.1	37.8	84.1	+77.8	10.9x
2	006910.KS	Boseong Powertech	0.933	96.5	20.3	18.2	+91.3	28.7x
3	062040.KS	Sanil Electric	0.930	93.5	29.2	35.6	+50.3	43.2x
4	058470.KS	Leeno Industrial	0.923	95.0	22.5	47.5	+33.9	61.8x
5	005690.KS	Pharmicell	0.921	80.2	38.3	30.1	+75.8	26.4x
6	307930.KS	Company K	0.912	84.5	9.3	45.2	+43.0	20.1x
7	420770.KQ	Gigavis	0.910	95.9	7.4	23.1	+100.8	75.1x
8	425420.KQ	TFI	0.909	93.6	19.3	17.1	+51.8	39.6x
9	000660.KS	SK Hynix	0.908	98.2	44.2	48.6	+46.8	20.8x
10	017510.KS	Semyung Electric	0.907	71.3	15.1	45.8	+124.3	13.1x

Top 3 in Focus

SK Square (402340.KS) — Score 0.966, P/E 10.9x SK Square is the investment holding company that owns a ~20% stake in SK Hynix along with a portfolio of tech subsidiaries (11Street, SK Shieldus, Incross). The 84.1% operating margin reflects the holding-company structure — essentially a leveraged play on SK Hynix’s semiconductor cycle at a significant NAV discount. At 10.9x trailing earnings, it is the cheapest name in the top-20 cohort by a wide margin, and its near-all-time-high RS (99.1 percentile) suggests the market is beginning to close that discount. The +77.8% revenue growth flags meaningful portfolio monetization on top of the HBM cycle tailwind.

Sanil Electric (062040.KS) — Score 0.930, P/E 43.2x Sanil manufactures power transformers and distribution equipment, sitting at the intersection of two secular capex waves: domestic grid modernization and data-center power supply. ROE of 29.2% and a 35.6% operating margin are exceptional for heavy electrical manufacturing, pointing to pricing power from a constrained supply base. Revenue growth of +50.3% YoY reflects backlog execution rather than demand pull-forward, making the 43x multiple more defensible than it appears on the surface.

Leeno Industrial (058470.KS) — Score 0.923, P/E 61.8x Leeno is the dominant Korean maker of semiconductor test sockets — the precision-machined contact pins that sit between IC chips and test equipment during quality control. With a 47.5% operating margin and ROE of 22.5%, Leeno operates a quasi-monopoly niche in a consumables-like business: sockets wear out with use, creating recurring revenue tied to wafer-out volumes. The premium multiple (61.8x) is the market paying for durability; the stock’s 95th-percentile RS confirms institutional patience with that valuation.

Korea Tenbaggers 2023-2026: Power Grid Beat the AI Hype

Thu, 23 Apr 2026 10:30:00 +0900

Series — KOSDAQ Structural 2026 (Part 3 of 3) ① KOSDAQ 2026 Capital Inflow Triggers & VC Ranking — the policy/capital setup ② KOSDAQ IPO Class of 2023-2026: Where the Tenbaggers Actually Live — the IPO-vintage winners ③ This post — the full KOSPI + KOSDAQ 3-year 10× census and what actually made the cut

The Headline Number: 27 out of 2,613

We ran the full 3-year census across KOSPI (836 names) and KOSDAQ (1,777 names, SPACs excluded) from early 2023 through April 2026.

Universe: 2,613 stocks
Passed 10×: 27 names
Hit rate: 1.03%

One in a hundred. That is the prior for “I’ll just buy a small-cap and hold three years.” The other 99 didn’t make it.

But the 27 that did are not random — they cluster hard into three sectors, and the factor profile is surprisingly classical.

The Full 27-Name Table

#	Name	Mult	Peak	DD from Peak	Rev YoY	Op YoY	Op Margin	ROE	P/E	Sector
1	HD Hyundai Electric	~20×	2025H2	-15%	+38%	+95%	18%	41%	14	Power/Grid
2	Hyosung Heavy	~16×	2025H2	-22%	+31%	+82%	14%	35%	13	Power/Grid
3	LS Electric	~14×	2025H2	-18%	+27%	+61%	12%	28%	16	Power/Grid
4	SK Hynix	~13×	2026Q1	-8%	+71%	+340%	42%	48%	9	Semis/AI
5	Isu Petasys	~22×	2024H2	-35%	+88%	n/m	18%	52%	11	Semis/AI (HBM PCB)
6	Hanwha Aerospace	~18×	2025H2	-12%	+44%	+110%	13%	32%	12	Defense
7	HD Hyundai Marine Engine	~15×	2025H2	-9%	+52%	+180%	16%	44%	10	Shipbuilding
8	Samyang Foods	~17×	2025H1	-20%	+47%	+125%	22%	46%	14	Consumer/Export
9	SK Square	~11×	2026Q1	-6%	n/m	n/m	n/m	31%	8	Holding/Semi
10	Alteogen	~25×	2024H2	-42%	+210%	n/m	n/m	n/m	n/m	Biotech
11	Ligachem Bio	~14×	2025H1	-28%	+95%	n/m	n/m	n/m	n/m	Biotech
12	HLB	~12×	2024H1	-55%	+12%	neg	neg	neg	n/m	Biotech
13	Peptron	~18×	2024H2	-48%	+180%	n/m	n/m	n/m	n/m	Biotech
14	ABL Bio	~11×	2025H1	-30%	+140%	n/m	n/m	n/m	n/m	Biotech
15	Doosan Enerbility	~13×	2025H2	-18%	+18%	+65%	9%	14%	22	Nuclear/Power
16	Hyundai Rotem	~14×	2025H2	-15%	+33%	+92%	11%	26%	15	Defense/Rail
17	Hanwha Ocean	~11×	2025H2	-16%	+28%	+70%	7%	18%	19	Shipbuilding
18	Iljin Electric	~12×	2025H2	-20%	+25%	+55%	10%	24%	17	Power/Grid
19	Daeho AL	~11×	2025H1	-24%	+35%	+88%	13%	29%	13	Grid materials
20	Jeio	~15×	2025H2	-30%	+120%	n/m	22%	38%	18	AI/Semi cap-eq
21	Park Systems	~10×	2025H1	-22%	+41%	+78%	24%	33%	24	Semi metrology
22	Hanjin Kal	~10×	2025Q3	-14%	+6%	+18%	n/m	11%	28	Holdings
23	Hyundai Motor Securities	~11×	2025H2	-18%	+22%	+45%	n/m	15%	11	Financials
24	Kiwoom Securities	~10×	2025H2	-15%	+19%	+38%	n/m	13%	9	Financials
25	Woori Financial	~10×	2026Q1	-5%	+8%	+14%	n/m	11%	7	Banks
26	Koh Young	~11×	2025H1	-28%	+25%	+60%	17%	22%	20	Semi inspection
27	Simmtech	~10×	2025H1	-32%	+55%	+140%	14%	34%	12	Semi substrate

Multiples are trough-to-peak trailing 3 years. “n/m” = not meaningful (loss-making or holding-company accounting). Figures rounded.

What Actually Made the Cut — The Sector Map

Collapse the 27 into clusters and the story rewrites itself:

Cluster	Count	Share
Power / Grid / Nuclear	8	30%
Semis / AI cap-eq	6	22%
Biotech	5	19%
Defense / Shipbuilding	3	11%
Financials	3	11%
Consumer (export)	1	4%
Holding (semi-adjacent)	1	4%

The consensus story was “AI semis.” That delivered — 6 names, led by SK Hynix and the HBM substrate/PCB complex. But the quiet cluster is power & grid: 8 of 27, and the top 3 by multiple (HD Hyundai Electric, Hyosung Heavy, LS Electric) all sit here. This is the datacenter-electrification, grid-capex, and nuclear-renaissance trade — and it ran without the retail hype that biotech and AI got.

Biotech is the opposite profile: 5 names, but average drawdown from peak is -41%. These are regime-dependent winners; the other 22 are averaging -18% from peak. If you time biotech wrong on exit, the realized return isn’t a tenbagger anymore.

Factor Decomposition — What Would Have Caught Them Ex-Ante

Of the 27:

74% are profitable at time of screening. The “lottery ticket loss-maker” stereotype fits only the biotech cluster.
7 names had ROE ≥ 40% ex-ante: Isu Petasys, SK Hynix, Samyang Foods, HD Hyundai Marine Engine, HD Hyundai Electric, Hyosung Heavy (borderline), Alteogen (once profitable). A pure ROE≥40% screen would have pulled the core industrial winners.
8 names had P/E ≤ 15 ex-ante: Woori Financial, SK Square, SK Hynix, Kiwoom Securities, HD Hyundai Marine Engine, Simmtech, Isu Petasys, Hyosung Heavy. Cheap-and-compounding is not a myth in Korea — it’s just rare.
Intersection (ROE≥40 AND P/E≤15): 5 names. 5 out of 2,613 — a 0.19% base rate, but a 100% hit rate inside the screen.

The naive two-factor quality+value screen, run blind in 2023, would have returned roughly 15-30 tickers across KOSPI+KOSDAQ. Five of them would have been tenbaggers. That is the real prior a retail investor should internalize.

Seven Fund-Manager Observations

The power-grid cluster is still under-owned by foreigners. Foreign ownership in HD Hyundai Electric and Hyosung Heavy only rebuilt after the move. The catalyst (datacenter transformer shortage, US grid capex) was legible by mid-2023.
HBM payout ≠ HBM narrative. SK Hynix paid 13×, but the top HBM-adjacent winner by multiple was Isu Petasys (~22×) — a PCB substrate name most foreigners still can’t pronounce. The derivative wins harder than the headline.
Defense and shipbuilding are the same trade. Hanwha Aerospace, Hyundai Rotem, Hanwha Ocean, HD Hyundai Marine Engine — NATO rearmament + LNG carrier super-cycle + nuclear-propulsion optionality. Four tenbaggers from one geopolitical regime change.
Biotech drawdowns are un-hold-able without process. HLB is still -55% from peak. If you bought at peak you lost money on a tenbagger. Position sizing rules matter more here than in any other cluster.
Financials printed 3 tenbaggers without a single analyst note calling it. Woori, Kiwoom, Hyundai Motor Securities — the value-up + rate-normalization + retail-brokerage trade. The boring trade worked.
Samyang Foods is the only consumer name and it happened because Buldak became a global export product. Consumer tenbaggers in Korea need an export wedge; the domestic market alone is too small.
Zero tenbaggers from the “platform/crypto/metaverse” bucket. Every single winner is a real-asset, real-earnings, real-capex business. The 2021 narrative cohort delivered nothing at the 10× mark.

A 7-Name Sector-Representative Portfolio

If the goal is to have owned one name per winning cluster, equal-weighted, the minimum-viable portfolio was:

Ticker theme	Name	Cluster
Power/Grid	HD Hyundai Electric	Transformers, datacenter capex
AI Semi	SK Hynix	HBM leader
HBM Derivative	Isu Petasys	PCB substrate, highest multiple
Defense	Hanwha Aerospace	K9, K2, rearmament
Shipbuilding	HD Hyundai Marine Engine	LNG + nuclear propulsion
Consumer Export	Samyang Foods	Buldak global demand
Holdings	SK Square	Hynix pass-through + cheap

Equal-weighted, rebalanced annually, this 7-name basket would have compounded at roughly 9-11× over the 3-year window (individual multiples 10-22×, diluted by rebalance). It is the cleanest statement of “what the 3-year KR tenbagger regime was actually made of.”

Caveats

Survivorship. This is the realized set. Ex-ante there were 50+ names that looked equally plausible and are now -30%.
Exit risk. Multiples are trough-to-peak. Real-world realized returns with timing imperfection are materially lower — especially in the biotech cluster.
Regime dependence. Power-grid and defense are driven by multi-year capex cycles that can roll over. Do not extrapolate 2023-2026 hit rates into 2026-2029 without re-checking the macro setup.
1.03% hit rate, not 10%. The base rate is brutal. Any strategy that doesn’t filter hard will dilute into the 99% that didn’t work.

Bottom Line

The 2023-2026 Korean market produced 27 tenbaggers out of 2,613 names. Three-quarters were profitable at the start. The hidden winner wasn’t AI — it was the power grid. A simple ROE≥40% + P/E≤15 screen, applied blind, would have caught a disproportionate share. And across all 27 winners, not one came from the narrative trades of 2021.

The boring trade — real assets, real earnings, real capex — won again.

This closes the KOSDAQ Structural 2026 series. Part 1: VC ranking and capital triggers. Part 2: IPO class of 2023-2026 tenbaggers.

KOSDAQ IPO Tenbaggers: 259 Firms, 3 Buckets and 11 Names

Wed, 22 Apr 2026 10:30:00 +0900

📚 Series 2/4: KOSDAQ Structural Deep-Dive — series hub →

Second entry. Prior: Korea’s 2026 KOSDAQ Policy Package — A VC-Practitioner Ranking of the Ten Active Capital-Inflow Triggers mapped the money-in channels. This post asks the opposite question: once the money arrives, where does it actually compound? The answer from the 2023-2026 new-listing cohort is surprisingly concentrated.

TL;DR

Of 308 KOSDAQ new listings from 2023-2026, exactly 49 are SPACs (identified by “SPAC” in the Korean ticker name). Strip those out and the real operating universe is 259 firms.

From that 259:

39 firms (15%) have returned +100% or more since IPO
33 firms (13%) are down -50% or worse
53% are still below the IPO price
44% of the winners cluster in 3 sector buckets — R&D (pharma pipeline), semiconductors, medical devices. Those three buckets hold 48 firms, barely 19% of the universe, but 17 of the 39 tenbaggers came from them.

The single strongest numerical signal: firms with YoY revenue growth above 200% show a 57% tenbagger hit rate (4 of 7). The next bucket (50–200% growth) drops to 29%. Above 200% is effectively a structural filter.

Below: the full decomposition, then an 11-name Tier 1 shortlist to move into qualitative review.

1. Redefining the universe: SPACs cleanly removed

The cleanest SPAC filter is the Korean ticker-name rule: any listed shell with “스팩” (SPAC) in the name. That removes 49 names across four cohorts — most heavily from the 2024 cohort (36 SPACs alone).

Names sometimes flagged as “shells” but which are genuine operating businesses and therefore kept: LB Investment, HB Investment, Capstone Partners (all three are VC fund managers with real carry revenue), Hanpass (FX remittance fintech), Terra View. These stay in.

Cohort	Raw B-universe	After SPAC removal
2023 IPOs	101	92
2024 IPOs	123	87
2025 IPOs	79	75
2026 IPOs (YTD April)	5	5
Total	308	259

2. Year-by-year post-IPO performance (operating firms only)

Cohort	N	Median revenue (KRW bn)	Operating-profit firms	Median ADT20 (KRW bn/day)	Median return since IPO	+100% firms	+500% firms	Loser rate	Median current drawdown
2023	92	32.9	34%	1.15	+0.4%	11 (12%)	0	49%	-29%
2024	87	26.9	49%	1.24	-25.5%	16 (18%)	4	61%	-42%
2025	75	50.1	39%	2.02	-20.2%	12 (16%)	1	57%	-48%
2026	5	35.2	60%	24.70	-40.7%	0	0	60%	-41%

Three observations that pay off later:

2024 is the paradox cohort. Median return -25.5% (worst of any year), but all four +500% winners came from 2024 — Sceers Medical, D&D Pharmatech, Samhyun, HVM. Classic high-variance distribution: the median gets crushed while the right tail produces the biggest hits.
2025 is the “expensive IPO of mature companies” cohort. Median revenue 50.1B KRW (highest of any year — these were real companies at scale), but -48% median drawdown from peak. Pricing was rich; de-rating is mechanical. The distribution suggests 12–18 months out, this cohort should throw off re-entry opportunities at de-rated multiples.
Operating-profit rate isn’t a quality signal here. 2024 had the highest profitability (49% of listings profitable at IPO) yet the weakest post-IPO returns. High profitability at listing correlates with “mature companies priced near fair value” — exactly the opposite of where tenbaggers come from.

3. Sector bucket performance (N≥8, covering 139 of 259 firms)

Sector	N	Median rev (bn)	Profit rate	Median ROE	Median P/E	Median YoY growth	Median return	p90 return	+100% hits	Loser rate
R&D (bio pipeline)	18	4.3	11%	-44%	55	+9%	+51.5%	+312%	7	33%
Semiconductors	16	20.2	19%	-18%	59	+6%	+47.3%	+215%	5	38%
Medical devices	14	20.6	50%	+3%	49	+36%	+14.2%	+260%	3	43%
Electronic components	13	81.9	46%	0%	44	+9%	-6.7%	+80%	1	54%
Special-purpose machinery	22	29.9	32%	-2%	26	-3%	+0.2%	+52%	2	50%
General machinery	9	45.0	44%	-5%	26	+14%	-17.5%	+21%	0	67%
Software	36	19.6	28%	-8%	25	+11%	-17.6%	+67%	2	61%
Other chemicals (incl. EV battery)	11	28.5	82%	+8%	42	-8%	-42.2%	-17%	1	91%

Three winner buckets

Bio R&D + Semiconductors + Medical devices = 48 firms, 19% of universe, but 17 of the 39 +100% hits (44%). That concentration is not noise — it reflects a structural reality:

Bio R&D winners compound on clinical milestones and out-licensing deals, not current revenue. So a firm can have 4.3bn KRW median revenue and still hit +312% at the p90.
Semiconductor winners ride specific cycles: HBM-adjacent, AI-server SSD, wafer-back-end. Five listings hit +100% with median P/E of 59x — the market pays for the asymmetric call on new memory architectures.
Medical devices have the highest profitability (50% profit rate) and a +260% p90. That combination is rare. Korean medical devices with FDA approval + US distribution are structurally underpriced because the local market doesn’t know how to value US-scale med-tech.

Two loser buckets

Software (36 firms) + Other chemicals (11 firms) = 47 firms, explaining most of the loser population.

Software is the “AI premium paid at IPO” problem. 61% loser rate. Thin moats, low switching cost, and the “AI wrapper” narrative deflated as soon as enterprise buyers got sober in mid-2024.
Other chemicals is the 2차전지 (secondary battery) peak-out. 91% loser rate (10 of 11 down). Battery-material listings rode the 2022-2023 EV mania into IPO and then met the 2024-2025 demand correction head-on.

The middle zone

Special-purpose machinery, electronic components, general machinery — all “real revenue, boring multiples, mean-reverting performance.” Median revenue 30-82bn KRW (the biggest of any bucket) but median return near zero. This is the classic Korean KOSDAQ equipment/parts segment: legitimate businesses, cyclically priced, no asymmetric upside at IPO.

4. The DNA of the 39 winners

Looking across all +100% firms:

Characteristic	Count	Read
Operating-profit firms	13/39 (33%)	Profitability is not the signal. Two-thirds of tenbaggers are still losing money at IPO.
ROE > 10%	10	The 10 profitable-and-high-ROE winners are the “earnings-compounding” subset
YoY revenue growth > 50%	13	One-third have clear top-line explosions
Revenue ≥ 20bn KRW	22/38	58% have minimum size already
Revenue ≥ 100bn KRW	4/38	Large-revenue names are rare among tenbaggers — the universe favors smaller bases
Median P/E (profitable subset)	54.5×	Winners already trade at growth multiples

The single strongest signal: YoY revenue growth buckets

YoY revenue growth bucket	N	Median return	+100% hits	Hit rate
200%+	7	+106.8%	4	57%
50–200%	31	+8.5%	9	29%
20–50%	42	+10.5%	6	14%
0–20%	72	-8.2%	9	13%
-20–0%	66	-24.4%	6	9%
≤-20%	36	-22.8%	4	11%

The 57% hit rate for the 200%+ bucket is the single most concentrated signal in the data. Seven names — priority research targets. Caveat: n=7 is small; treat the number as a direction, not a probability estimate for the next cohort.

5. Top 10 winners — current state

Ticker	Sector	IPO	Return	Peak DD	Revenue (bn)	YoY growth
Sceers Medical	Medical device	2024-06	+1,111%	-31%	48.2	+495%
D&D Pharmatech	Bio R&D	2024-05	+1,011%	-27%	4.3	-62%
Samhyun	Auto parts	2024-03	+635%	-26%	95.0	-5%
HVM	Non-ferrous metals	2024-06	+614%	-19%	66.5	+47%
Rokit Healthcare	Medical supplies	2025-05	+526%	-38%	26.2	+100%
Tomocube	Optics	2024-11	+444%	-17%	11.3	+91%
Onconic Therapeutics	Bio R&D	2024-12	+421%	-14%	53.4	+261%
Sammi Metal	Metal fabrication	2025-12	+411%	-20%	73.8	-3%
Klobot	Software (robotics)	2024-10	+391%	-35%	41.4	+24%
Fadu	Semiconductor	2023-08	+338%	-14%	92.4	+112%

Notable pattern: 7 of the Top 10 are currently in -25% to -40% drawdown from their post-IPO peak. “One tenbagger move, then a 30% reset” is the modal pattern. From a re-entry-timing perspective, this is the window that matters most — the tenbagger already proved the structural story; the drawdown is about positioning, not about the thesis breaking.

Top losers — the opposite side: E8 (-87%, game/AI SW post-IPO dump), Chi Communication (-82%, China advertising), TDS Pharma (-80%, generics), DaeJin Advanced Materials (-77%, battery-materials loser), M83 (-69%, film production). Common pattern: story-driven overpricing → earnings vacuum → collapse.

6. From universe to shortlist: the Tier 1 11

Combining (a) the three winner buckets, (b) revenue in the 20-150bn KRW “meaningful but not saturated” zone, (c) clear top-line growth in the last 12 months, and (d) either ongoing drawdown (re-entry) or live catalyst (new positioning), the following 11 names emerge as Tier 1 for qualitative review.

Bio R&D (2)

#	Name	IPO	Rev (bn)	ROE	Return	DD	Thesis
1	Onconic Therapeutics	24-12	53.4	+24.6%	+421%	-14%	Subsidiary of Jeil Pharmaceutical. Jaktinib (reflux therapeutic) out-licensed to China and India, US trials advancing. Only profitable firm in the 18-stock bio R&D bucket with real revenue scale. Next leg needs additional out-licensing or US milestone.
2	D&D Pharmatech	24-05	4.3	-31.5%	+1,011%	-27%	GLP-1-based obesity and Parkinson’s pipeline. Already the biggest 2024 winner. Valuation stretched — next leg requires clinical data readout. Re-entry window is narrow.

Semiconductors (5)

#	Name	IPO	Rev (bn)	YoY	ROE	Return	3M	DD	Thesis
3	Green Resource	23-11	102.2	+452%	+15.9%	+151%	+193%	0%	Quartz/ceramic materials for semiconductor processes. Samsung/Hynix vendor. Revenue 4× explosion. Currently at fresh highs — entry should wait for correction.
4	Fadu	23-08	92.4	+112%	-131%	+338%	+186%	-14%	SSD controller SoC. Data-center/enterprise SSD (Meta-style) order recovery. Direct AI-server exposure.
5	Sapien Semiconductor	24-02	17.3	+116%	-33%	+140%	+11%	-14%	Micro-LED pixel driver IC. Apple Vision Pro / AR-glasses-class forward investment. Revenue inflection just starting.
6	Qualitas Semiconductor	23-10	5.4	-12%	-53%	+65%	+55%	-7%	SerDes (high-speed interconnect) IP. SK Hynix cooperation + HBM-adjacent SerDes demand. IP royalty model — likely J-curve inflection point.
7	Wavics	(listed in period)	40.7	—	—	—	+87%	—	RF GaN semiconductors. Defense + comms dual exposure. Only domestic mass producer of GaN-on-SiC.

Medical devices (4)

#	Name	IPO	Rev (bn)	YoY	ROE	Return	DD	Thesis
8	Sceers Medical	24-06	48.2	+495%	+52.8%	+1,111%	-31%	AI ECG monitoring device. Revenue + ROE + growth triple-compounding. Most structurally complete medical-device tenbagger. In -31% correction.
9	Livsmed	25-12	51.2	+89%	-21%	+17%	-36%	“ArtiSential” laparoscopic multi-articulating instrument. US/EU launch accelerating. Recent IPO + revenue 51bn + growth +89% + DD -36% — rare 4-factor alignment.
10	Nextbiomedical	24-08	16.5	+74%	0%	+135%	-37%	FDA-approved “Nexsphere” embolization product. US revenue ramp imminent.
11	Asterasys	25-01	37.9	+32%	+27.7%	+79%	-26%	HIFU ultrasound skin-treatment device “Liftera.” Korea / China / Middle East demand. Top-quartile ROE among profitable medical-device IPOs.

7. What this framework actually says

Question	Answer from the 259-firm backtest
Base rate of finding a +100% winner at KOSDAQ IPO	15% (39/259)
Base rate of finding a +500% winner	1.9% (5/259)
Worst cohort to chase	2024 at listing (median -25.5%, 61% losers — though the right-tail winners came from here)
Best cohort to hunt in right now	2025 (richest base — median revenue 50bn — currently at -48% median drawdown)
Single most predictive metric	YoY revenue growth ≥ 200% → 57% hit rate
Sectors to live in	Bio R&D, semiconductors, medical devices (44% of winners, 19% of universe)
Sectors to skip	Software (61% loser rate), secondary-battery chemicals (91% loser rate)

The framework isn’t a prediction engine. It’s a base-rate engine. It says: given how money has actually been made in new KOSDAQ listings over the last three years, these 11 names sit on more of the right factors than any others in the cohort. Qualitative review comes next — IR material, disclosure history, consensus positioning — and position sizing follows that.

8. Caveats and honest uncertainties

YoY growth percentages are noisy in bio R&D. Most have base revenues of 3-10bn KRW, so a “+7,800%” print (Algenomics) is the jump from 100M to 8bn — a milestone payment, not a business inflection. For bio names, look at absolute revenue + pipeline milestones, not YoY %.
Fundamentals are an 8-day snapshot. The ROE/P/E here come from the 2026-04-14 through 04-21 filings window. Next quarterly reports will reshuffle some of these names.
Green Resource, Fadu, Sonics — 3-month momentum ≥ +180%. Chasing these here carries a sharp drawdown risk. The Tier 1 placement reflects structural fit, not “buy now.”
Re-entry on past +1,000% winners. D&D Pharmatech and Sceers Medical have already delivered 10×. Another 5-10× from here requires a new catalyst — new market, new indication, new geography. Without it, the base case is mean reversion.
Consensus / target-price fields are empty in our data. Sell-side positioning isn’t reflected. IR contact and disclosure-level review is mandatory before sizing.

9. What’s next

This post closed the loop started by the VC-practitioner policy ranking: money-in channels → where the money actually compounds. Two pieces of the same structural view of KOSDAQ 2026.

Next on the research stack: Tier 1 single-name deep-dives — starting with the two names where the thesis is simultaneously (a) fundamentally strong, (b) technically in a constructive drawdown, and (c) within our existing framework. Onconic Therapeutics and Livsmed are the likely first targets.

Korea Daily Wrap 2026-04-21: Smart Money Chases Earnings Inflection

Tue, 21 Apr 2026 16:30:00 +0900

Macro Dashboard

Indicator	Level	5D Change	Signal
KOSPI	6,388.5	+4.9%	Bullish
KOSDAQ	1,179.0	+2.3%	Bullish
USD/KRW	1,470	+0.0%	Neutral
VIX	18.8	+3.6%	Stable
US 10Y	4.25%	-0.01pp	Flat
Brent	$90.6	-8.9%	Easing

Regime Verdict — KR: Bull | US: Bull. Both markets are in confirmed bull regime. KOSPI’s 5-day surge of nearly 5% runs alongside a 64.2% breadth above the 50MA and 59.3% above the 200MA — broad participation, not a narrow spike. Declining Brent removes an inflationary overhang for Korean manufacturers. USD/KRW holding at 1,470 is constructive; the won is not pressuring import costs or foreign flows. Stance: aggressive expansion.

Market Wrap

Tuesday’s Korea session carried the hallmarks of a conviction rally rather than a reflex bounce. KOSPI closed at 6,388 — up nearly 300 points over five sessions — with breadth firmly above key moving averages, suggesting institutional rotation rather than retail-driven momentum.

Sector character: Machinery and special-purpose equipment were the day’s standout performers. The screener universe is saturated with industrial names flagging simultaneous volume surges, near-52-week highs, and triple-digit operating income growth — a combination that typically reflects a genuine demand cycle rather than a valuation re-rate. Display equipment, semiconductor test gear, and shipbuilding-adjacent components all saw buying pressure consistent with a capex supercycle narrative gaining credibility.

Semiconductors: The memory complex continued to command attention. Foreign buyers have maintained exposure to large-cap semis even as the broader global tape has been volatile. The earnings improvement signals are coming through cleanly — revenue growth, margin expansion, and ROE recovery all aligning simultaneously.

Defense & Heavy Industry: Defense-adjacent names (small arms components, naval propulsion) appeared among smart money candidates, reflecting the sustained re-armament theme that has been running since late 2025. Order backlogs are translating into visible P&L inflection, and institutional accumulation appears to be tracking that inflection with a 1-2 quarter lag.

Power & Electrical Equipment: Transformer and power conversion names continue to benefit from global grid buildout demand — a theme with multi-year duration that is now showing up in actual earnings prints, not just forward estimates.

Energy tailwind: Brent’s 8.9% five-day decline is a quiet positive for Korea’s energy-import-heavy industrial base. Lower feedstock and fuel costs expand margins at downstream manufacturers without requiring revenue growth — a silent earnings upgrade.

Foreign flows remain constructive. The smart money composite scores across today’s top candidates skew toward names with confirmed foreign and institutional accumulation (Vol+, RS85+, NearHigh tags), not speculative rotation. That distribution matters: it implies follow-through probability is higher than typical momentum screens.

Risk flags: VIX nudged up 3.6% over five days to 18.8 — still well within the stable band, but worth monitoring. A VIX break above 20 would warrant a defensive reassessment.

Today’s Screener Spotlight: Smart Money + Earnings Improvement

Tuesday’s screener combines institutional/foreign flow signals with fundamental earnings inflection criteria — revenue growth, operating income expansion, margin improvement, and ROE recovery must all be trending in the same direction. The goal is to surface names where smart capital is already accumulating ahead of consensus recognizing the earnings turn.

Today’s universe: 2,722 Korean listed names screened down to 20 top candidates (avg strategy score: 0.793). Zero names cleared all hard-filter thresholds simultaneously, but the ranked candidates show compelling partial scores.

Top 10 Candidates

Rank	Ticker	Name	Score	RS %ile	Rev Gth YoY	Op Inc Gth YoY	NI Gth YoY	Op Margin Δ	ROE Δ
1	171090.KQ	선익시스템	0.838	96.0	+357%	+1,311%	—	+14.6pp	+149pp
2	088130.KQ	동아엘텍	0.836	97.3	+227%	+670%	—	+11.2pp	+55pp
3	402340.KS	SK스퀘어	0.815	99.0	+78%	+124%	+142%	+17.5pp	+16pp
4	000660.KS	SK하이닉스	0.813	98.3	+47%	+101%	+117%	+13.1pp	+13pp
5	425420.KQ	티에프이	0.810	92.9	+52%	+334%	+1,107%	+11.1pp	+17pp
6	082740.KS	한화엔진	0.802	84.1	+14%	+82%	+119%	+3.5pp	+11pp
7	278470.KQ	에이피알	0.800	97.6	+111%	+198%	+169%	+7.0pp	+34pp
8	053610.KQ	프로텍	0.793	95.8	+35%	+246%	+179%	+12.2pp	+7pp
9	046940.KQ	우원개발	0.791	85.8	+24%	+2,300%	+6,757%	+16.9pp	+36pp
10	420770.KQ	기가비스	0.788	96.5	+101%	—	+356%	+29.9pp	+6pp

Top 3 Deep-Dive

#1 — 선익시스템 (171090.KQ) is a display deposition equipment maker focused on OLED evaporation systems. Revenue nearly quadrupled year-on-year, and operating income is up 13x — driven by a surge in panel maker capex as foldable and large-format OLED capacity expands in Korea and China. The ROE delta of +149pp signals a business moving from breakeven to highly profitable in a single cycle. Smart money score of 0.748 with RS at 96th percentile indicates institutions are already positioned.

#2 — 동아엘텍 (088130.KQ) manufactures precision display bonding and assembly equipment. The +670% operating income growth on +227% revenue suggests strong operating leverage — costs are not scaling with revenue. Near-52-week-high tag alongside volume expansion is a technical confirmation of the fundamental thesis. Sector overlap with 선익시스템 (both in display capex) raises portfolio concentration risk if held together.

#3 — SK스퀘어 (402340.KS) is SK Telecom’s investment holding arm, with stakes in SK하이닉스 and a portfolio of Korean tech ventures. At RS 99th percentile, it is the relative-strength leader in the large-cap space. The +17.5pp operating margin swing and +142% net income growth reflect semiconductor cycle recovery flowing up through the holding structure. It offers indirect semiconductor exposure with a financial-sector label — a structural mispricing some foreign funds exploit.

Data as of 2026-04-21 16:09 KST. Screener scores are quantitative signals, not investment recommendations. Always verify fundamentals independently.